WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen,
Inc. (NASDAQ: IMGN), a biotechnology
company that develops targeted anticancer therapies using its
antibody-drug conjugate (ADC) technology, today announced the
appointment of Sandra E. Poole as Senior Vice President, Technical
Operations. Ms. Poole brings to ImmunoGen more than 25 years of
experience related to the development and manufacturing of innovative
biopharmaceuticals, most recently as the senior vice president of
biologics manufacturing at Genzyme. She reports to Daniel Junius,
President and Chief Executive Officer of ImmunoGen.
"Sandra joins ImmunoGen in a newly established position that reflects
our advancing, broadening pipeline and escalating preparations for
later-stage clinical trials," commented Mr. Junius. "She brings
extensive experience successfully leading complex biologics operations,
integrating functions that include process development, production, and
quality assurance."
Prior to ImmunoGen, Ms. Poole had a 15-year career with Genzyme that
spanned a wealth of bio-manufacturing-related functions with increasing
responsibility, including heading up technology development, overseeing
the construction, start-up, tech transfer and approval of a fully
integrated manufacturing operation in Belgium and, most recently,
leading Genzyme's global network of biologic manufacturing sites.
Prior to joining Genzyme in 1999, Ms. Poole oversaw process development
and played a key role in establishing technical operations at
Canadian-based Biomira, Inc. She holds both a Master and a Bachelor of
Applied Science degree from the University of Waterloo (Canada) in
chemical engineering and also completed the executive program in
business management at the Massachusetts Institute of Technology Sloan
School of Management.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's
ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen
cell-killing agent specifically to cancer cells; the Company has also
developed antibodies with anticancer activity of their own. The first
product with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen
has three wholly owned product candidates in clinical testing with
additional compounds in clinical testing through the Company's
partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More
information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of
the Roche Group.
For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
info@immunogen.com
or
For
Media:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
Source: ImmunoGen, Inc.
News Provided by Acquire Media